Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70
Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.
How this was made
The 30-second read
Why it matters
Analyst downgrade with a target below current price may trigger short‑term selling, but the earnings beat and strategic collaborations could limit the decline.
Market read
Tempus AI's earnings beat and analyst downgrade together shape short‑term price action, while its pipeline and partnerships influence longer‑term outlook.
What to watch
Potential FDA approvals for xR and xF pipelines and the long‑term Bristol Myers Squibb partnership may provide upside not fully reflected in the new target.
Background
Tempus AI is a data‑driven precision‑medicine company that has been expanding its diagnostics and data‑applications segments.
Ticker impact
Jefferies upgraded Tempus AI (TEM) to Hold and cut its price target to $70, while the company posted Q3 2026 earnings that beat estimates and achieved positive EBITDA.
likely pressure as the market prices in the reduced target and Hold rating
Analyst downgrade with a target below current price typically triggers sell‑offs, even after a beat.
Market effects
The upgrade may temper enthusiasm for AI‑focused health‑tech stocks, but the earnings beat could buoy the broader data‑analytics sector.
U.S. market participants may adjust exposure to biotech‑AI hybrids.
Limited; impact confined to U.S. listed AI‑health companies.
Counterpoint
Despite the downgrade, the strong earnings beat and positive cash flow could support a rebound if the market overreacts to the lower target.
Key entities
- analystJefferies
Equity research firm that issued the upgrade and new price target.
- partnerBristol Myers Squibb
Long‑term collaboration partner mentioned in the earnings release.
